Quantification of a methadone metabolite (EDDP) in urine: Assessment of compliance

Clinical Medicine and Research

Volumn 7, Issue 4, 2009, Pages 134-141

  Larson, Michael E M ^a   Richards, Thomas M ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Chronic pain; Creatinine; Drug abuse; EDDP; Methadone; Urine specimen

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; CREATINE; METHADONE; MORPHINE; OXYCODONE;

ADULT; ARTICLE; BODY HEIGHT; BODY SIZE; BODY WEIGHT; CHRONIC PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG DEPENDENCE; FEMALE; GROUPS BY AGE; HUMAN; MALE; MEDICAL RECORD; PAIN; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SUBSTANCE ABUSE; URINALYSIS;

ANALGESICS, OPIOID; CHRONIC DISEASE; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; MONITORING, PHYSIOLOGIC; PAIN; PYRROLIDINES; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; WISCONSIN;

EID: 74749108986     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2009.859     Document Type: Article

References (38)

1. Barbanel CS, Winkelman JW, Fischer GA, King AJ. Confirmation of the Department of Transportation criteria for a substituted urine specimen. J Occup Environ Med 2002;44:407-416.
2. Kapur B, Hershkop S, Koren G, Gaughan V. Urine fingerprinting: detection of sample tampering in an opiate dependency program. Ther Drug Monit 1999;21:243-250.
3. Kintz P, Tracqui A, Mangin P, Edel Y. Sweat testing in opioid users with a sweat patch. J Anal Toxicol 1996;20:393-397.
4. Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, Cone EJ. Monitoring cocaine use in substance-abuse treatment patients by sweat and urine testing. J Anal Toxicol 1999;23:313-322.
5. Couto JE, Romney MC, Leider HL, Sharma S, Goldfarb NI. High rates of inappropriate drug use in the chronic pain population. Popul Health Manag 2009;12:185-190.
6. Preston KL, Epstein DH, Davoudzadeh D, Huestis MA. Methadone and metabolite urine concentrations in patients maintained on methadone. J Anal Toxicol 2003;27:332-341.
7. Poortmans JR, Auquier H, Renaut V, Durussel A, Saugy M, Brisson GR. Effect of short-term creatine supplementation on renal responses in men. Eur J Appl Physiol Occup Physiol 1997;76:566-567.
8. Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. Med Sci Sports Exerc 1999;31:1108-1110.
9. Alessio L, Berlin A, Dell'Orto A, Toffoletto F, Ghezzi I. Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators. Int Arch Occup Environ Health 1985;55:99-106.
10. Bingham SA, Cummings JH. The use of creatinine output as a check on the completeness of 24-hour urine collections. Hum Nurt Clin Nutr 1985;39:343-353.
11. Tietz N. Textbook of clinical chemistry. Philadelphia, PA: WB Saunders Co; 1986. 1279-1290.
12. Narayanan S, Appleton HD. Creatinine: a review. Clin Chem 1980;26:1119-1126.
13. Butler AR. The Jaffé reaction. Identification of the coloured species. Clin Chim Acta 1975;59:227-232.
14. Baugh LD, Liu RH, Walia AS. Simultaneous gas chromatography/mass spectrometry assay of methadone and 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in urine. J Forensic Sci 1991;36:548-555.
15. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
16. halls.md. Formulas for calculating body surface area (BSA). Available at: http://www.halls.md/body-surface-area/refs.htm. Accessed July 2003.
17. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, North Carolina, SAS Institute Inc., 1996.
18. Neter J, Wasserman W. Applied Linear Statistical Models. Homewood, Illinois, Richard D. Irwin, 1974.
19. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 suppl):S76-S82.
20. Hawks RL. Developments in cannabinoid analyses of body fluids: implications for forensic applications. In: Agurell S, Dewey W, Willette R, eds. The cannabinoids: chemical, pharmacologic and therapeutic aspects. Rockville, Maryland: Academic Press; 1983:1-12.
21. Bell R, Taylor EH, Ackerman B, Pappas AA. Interpretation of urine quantitative 11-nor-delta-9 tetrahydrocannabinol-9-carboxylic acid to determine abstinence from marijuana smoking. J Toxicol Clin Toxicol 1989;27:109-115.
22. Lafolie P, Beck O, Blennow G, Boréus L, Borg S, Elwin CE, Karlsson L, Odelius G, Hjemdahl P. Importance of creatinine analyses of urine when screening for abused drugs. Clin Chem 1991;37:1927-1931.
23. Manno J, Ferslew KE, Manno BR. Urine excretion patterns of cannabinoids and the clinical application of the EMIT-dau cannabinoid urine assay for substance abuse treatment. In: Agurell A, Dewey WE, Willet RE, eds. The cannabinoids: chemical pharmacologica and therapeutic aspects. New York: Academic Press; 1984:281.
24. Painter PC, Evans JH, Greenwood JD, Fain WW. Urine cannabinoids monitoring. Diag Clin Testing 1989;27:29-33.
25. Jones AW, Karlsson L. Relation between blood- and urine-amphetamine concentrations in impaired drivers as influenced by urinary pH and creatinine. Hum Exp Toxicol 2005;24:615-622.
26. Weiss RD, Gawin FH. Protracted elimination of cocaine metabolites in long-term high-dose cocaine abusers. Am J Med 1988;85:879-880.
27. Thompson SG, Barlow RD, Wald NJ, Van Vunakis H. How should urinary cotinine concentrations be adjusted for urinary creatinine concentration? Clin Chim Acta 1990;187:289-295.
28. Watson ID. Analysis of commonly abused drugs in urine at selected threshold (cutoff) concentrations. Clin Chem 1992;38:441.
29. Cone EJ, Lange R, Darwin WD. In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 1998;22:460-473.
30. Needleman SB, Porvaznik M, Ander D. Creatinine analysis in single collection urine specimens. J Forensic Sci 1992;37:1125-1133.
31. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int 2003;133:26-31.
32. Huestis M, Cone E. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998;22:445-454.
33. Cone EJ, Caplan YH, Moser F, Robert T, Shelby MK, Black DL. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol 2009;33:1-7.
34. Berndt S, Maier C, Schütz HW. Polymedication and medication compliance in patients with chronic non-malignant pain. Pain 1993;52:331-339.
35. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence and predictors. Clin J Pain 1997;13:150-155.
36. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18:27-37.
37. Ready LB, Sarkis E, Turner JA. Self-reported vs. actual use of medications in chronic pain patients. Pain 1982;12:285-294.
38. Sees KL, Clark HW. Opioid use in the treatment of chronic pain: assessment of addiction. J Pain Symptom Manage 1993;8:257-264.